1
|
Jebali J, Zakraoui O, Aissaoui D, Abdelkafi-Koubaa Z, Srairi-Abid N, Marrakchi N, Essafi-Benkhadir K. Lebecetin, a snake venom C-type lectin protein, modulates LPS-induced inflammatory cytokine production in human THP-1-derived macrophages. Toxicon 2020; 187:144-150. [PMID: 32918926 DOI: 10.1016/j.toxicon.2020.09.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 08/11/2020] [Accepted: 09/07/2020] [Indexed: 10/25/2022]
Abstract
The excessive production of inflammatory mediators results in an overactive immune response leading to the worsening of various human diseases. Thus, there is a still need to identify molecules able to regulate the inflammatory response. Lebecetin, a C-type lectin protein isolated from Macrovipera lebetina snake venom, was previously characterized as a platelet aggregation inhibitor and antitumor active biomolecule. In the present work, we investigated its effect on the production of some cytokines linked to inflammatory response and the underlying mechanisms in lipopolysaccharide (LPS)-induced THP1 macrophages. Interestingly, we found that lebecetin reduced the levels of the pro-inflammatory cytokines TNF-α, IL-6, and IL-8 while it partially increased LPS-induced secretion of the immunomodulatory cytokine IL-10. Furthermore, this modulatory effect was accompanied by decreased activation of ERK1/2, p38, AKT kinases and NF-κB along with reduced expression of αvβ3 integrin. Thus, this study highlights the promising role of lebecetin as a natural biomolecule that could manage the inflammatory response involved in the development and progression of inflammatory diseases.
Collapse
Affiliation(s)
- Jed Jebali
- Institut Pasteur de Tunis, LR11IPT08/LR16IPT08 Laboratoire des Venins et Molécules Thérapeutiques, 1002, Tunis, Tunisia; Université de Tunis El Manar, 1068, Tunis, Tunisia.
| | - Ons Zakraoui
- Institut Pasteur de Tunis, LR11IPT04/LR16IPT04 Laboratoire d'Epidémiologie Moléculaire et de Pathologie Expérimentale Appliquée Aux Maladies Infectieuses, 1002, Tunis, Tunisia; Université de Tunis El Manar, 1068, Tunis, Tunisia
| | - Dorra Aissaoui
- Institut Pasteur de Tunis, LR11IPT08/LR16IPT08 Laboratoire des Venins et Molécules Thérapeutiques, 1002, Tunis, Tunisia; Université de Tunis El Manar, 1068, Tunis, Tunisia
| | - Zaineb Abdelkafi-Koubaa
- Institut Pasteur de Tunis, LR11IPT08/LR16IPT08 Laboratoire des Venins et Molécules Thérapeutiques, 1002, Tunis, Tunisia; Université de Tunis El Manar, 1068, Tunis, Tunisia
| | - Najet Srairi-Abid
- Institut Pasteur de Tunis, LR11IPT08/LR16IPT08 Laboratoire des Venins et Molécules Thérapeutiques, 1002, Tunis, Tunisia; Université de Tunis El Manar, 1068, Tunis, Tunisia
| | - Naziha Marrakchi
- Institut Pasteur de Tunis, LR11IPT08/LR16IPT08 Laboratoire des Venins et Molécules Thérapeutiques, 1002, Tunis, Tunisia; Université de Tunis El Manar, 1068, Tunis, Tunisia; Faculté de Médecine de Tunis, Tunis, Tunisia
| | - Khadija Essafi-Benkhadir
- Institut Pasteur de Tunis, LR11IPT04/LR16IPT04 Laboratoire d'Epidémiologie Moléculaire et de Pathologie Expérimentale Appliquée Aux Maladies Infectieuses, 1002, Tunis, Tunisia; Université de Tunis El Manar, 1068, Tunis, Tunisia.
| |
Collapse
|